+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients



Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients



Cancer Immunology Immunotherapy 49(10): 537-543



Introduction: Therapies with granulocyte/macrophage-colony-stimulating factor (GM-CSF) and interleukin(IL)-2 are designed to activate macrophages and lymphocytes. We investigated whether combined treatment with GM-CSF and IL-2 induced macrophage-mediated antitumor activity and/or T-cell-mediated antitumor activity in lung cancer patients. Patients and methods: Macrophages in the pleural cavity (PCM), lymphocytes in the pleural cavity (PLY), and peripheral blood lymphocytes (PBL) were separated from 48 patients with resectable lung cancer. Lymphokine-activated killer (LAK) activity was assayed by measuring 51Cr release. The proportion of PCM positive for the GM-CSF receptor (GM-CFSR) alpha chain was examined by flow-cytometric analysis and the expression of GM-CSFR alpha chain mRNA in PCM was examined by reverse transcription/polymerase chain reaction analysis. Results: Treatment with GM-CSF developed no significant antitumor activity in PCM, PLY, or PBL. LAK activity was developed by PLY and PBL after incubation with IL-2. Stimulation with GM-CSF augmented LAK activities in PLY and PBL significantly, when these cells were cultured with autologous PCM (P < 0.05, P < 0.01). Moreover, GM-CSFR-alpha-chain-positive PCM had a higher potential to augmented LAK activities in PLY and PBL than had GM-CSFR-alpha-chain-negative PCM. Conclusion: These findings suggest that GM-CSF may stimulate GM-CSFR-alpha-chain-positive PCM and that these PCM may augment LAK activities developed by PLY and PBL. Combined treatment with GM-CSF and IL-2, therefore, may be a reasonable approach to treating lung cancer patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010723541

Download citation: RISBibTeXText

PMID: 11129324

DOI: 10.1007/s002620000144


Related references

Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 42: 877, 2001

Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Japanese Journal Of Cancer Research. 86(9): 861-866, 1995

Granulocyte macrophage colony stimulating factor augments interleukin 2 induced lymphokine activated killer cell activity. Clinical Research 38(2): 552A, 1990

An open-label, randomized trial of the effects of macrophage versus granulocyte colony-stimulating factor on natural killer cell activity, lymphokine activated killer cell activity, interleukin-2 production, and leukocyte count in patients after chemotherapy for ovarian cancer. Current Therapeutic Research. 58(10): 698-705, 1997

Lack of stimulative effect of granulocyte macrophage colony stimulating factor on lymphokine activated killer and adherent lymphokine activated killer cell cultures. Natural Immunity & Cell Growth Regulation 10(3): 136, 1991

Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells. Japanese Journal of Cancer Research 80(7): 662-669, 1989

Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Blood 81(10): 2671-2678, 1993

Effect of the hemopoietic growth factors il 3 and granulocyte macrophage colony stimulating factor on susceptibility of human myeloid leukemic cells to lymphokine activated killer activity. Natural Immunity & Cell Growth Regulation 10(3): 134-135, 1991

Enhanced human lymphokine-activated killer cell function after exposure to granulocyte-macrophage-colony stimulating factor. Cancer 76(7): 1253-1260, 1995

Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer 76(7): 1253-1260, 1995

Effects of recombinant granulocyte macrophage colony stimulating factor gm csf on induction of lymphokine activated killer lak cells in vitro. Experimental Hematology 18(6): 609, 1990

Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes. International Journal of Cancer 44(1): 170-176, 1989

Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor. Cancer Research 49(18): 5037-5043, 1989

The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro. International Journal of Immunopharmacology 13(5): 587-593, 1991

Susceptibility of monocytes to lymphokine activated killer cell lysis effect of granulocyte macrophage colony stimulating factor gm csf and interleukin 3 il3. FASEB Journal 3(3): A490, 1989